Publications by authors named "Muhammad Nassrum Massi"
Ann Med Surg (Lond)
January 2022
Article Synopsis
- - Approximately 70% of breast cancers are estrogen receptor-α (ERα)-positive, and tamoxifen, a selective ER modulator, is commonly used in treatment, but resistance to it can occur, often involving microRNAs like miR-221.
- - A study compared breast cancer patients with and without local or metastatic recurrence after at least one year of tamoxifen therapy, focusing on the expression levels of miR-221.
- - Results showed significantly higher expression of miR-221 in tamoxifen-resistant cases, suggesting that miR-221 may serve as a potential biomarker for predicting resistance to tamoxifen treatment in breast cancer patients.
